Apixaban Dosing for Cancer-Associated Venous Thromboembolism
For cancer-associated VTE, initiate apixaban at 10 mg orally twice daily for 7 days, then reduce to 5 mg twice daily for at least 6 months. After completing 6 months of anticoagulation, you can safely reduce to 2.5 mg twice daily for extended secondary prevention 1, 2, 3.
Initial Treatment Phase (First 7 Days)
Start with apixaban 10 mg orally twice daily for 7 days 1, 2, 3. This loading dose does not require parenteral anticoagulation bridging, unlike dabigatran or edoxaban 1.
Critical caveat: Exercise caution in patients with gastric or gastroesophageal malignancies, as DOACs carry increased bleeding risk in these populations 4, 2, 1. For these patients, LMWH (dalteparin or enoxaparin) remains preferred 2, 5.
Long-Term Treatment (Months 1-6)
After the initial 7 days, reduce to 5 mg orally twice daily and continue for at least 6 months 1, 2, 3. This dosing is supported by the Caravaggio trial, which demonstrated that apixaban was noninferior to dalteparin for preventing recurrent VTE (5.6% vs 7.9%) without increased major bleeding (3.8% vs 4.0%) 6.
The 2024 NCCN guidelines designate apixaban as Category 1 for DVT/PE in cancer patients, making it a preferred option alongside LMWH 2. The 2023 ASCO guidelines similarly recommend apixaban as an alternative to LMWH for long-term anticoagulation 7.
Extended Secondary Prevention (Beyond 6 Months)
After completing 6 months of full-dose therapy, reduce to 2.5 mg orally twice daily for extended prevention 1, 3. This recommendation is now strongly supported by the 2025 API-CAT trial (n=1,766), which demonstrated that reduced-dose apixaban was noninferior to full-dose for preventing recurrent VTE (2.1% vs 2.8%) while significantly reducing clinically relevant bleeding (12.1% vs 15.6%, p=0.03) 8.
The reduced dose provides:
- Comparable efficacy for VTE prevention (adjusted subhazard ratio 0.76,95% CI 0.41-1.41)
- 25% reduction in bleeding risk compared to continuing full dose
- No difference in mortality (17.7% vs 19.6%) 8
Dosing Adjustments
Reduce the dose by 50% if coadministering with combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) 3. For patients already on 2.5 mg twice daily, avoid these drug combinations entirely 3.
Renal impairment considerations:
- Apixaban is acceptable with creatinine clearance ≥30 mL/min 4, 2
- Avoid in severe renal impairment (CrCl <15 mL/min) 9
- Unlike LMWH, apixaban does not require dose adjustment for moderate renal dysfunction 4
Duration of Therapy
Continue anticoagulation as long as cancer remains active 4, 10, 5. The 2022 ITAC guidelines emphasize that extended therapy should persist throughout active malignancy, with annual reassessment of risks and benefits 4.
For patients who complete cancer treatment and achieve remission, consider stopping anticoagulation after 6-12 months, though this decision requires individualized assessment of residual thrombotic risk 4.
Key Clinical Pitfalls
Gastrointestinal malignancies: The SELECT-D and Hokusai-VTE Cancer trials showed increased GI bleeding with DOACs in esophageal and gastroesophageal cancers 1, 5. In these patients, LMWH remains the safer choice 2, 5.
Drug interactions: Cancer patients frequently receive chemotherapy with significant CYP3A4 interactions. Always verify compatibility before prescribing apixaban 2, 7.
Switching anticoagulants: If transitioning from warfarin, start apixaban when INR <2.0. When switching from LMWH, begin apixaban at the time of the next scheduled LMWH dose 3.
The evidence strongly supports apixaban as a first-line option for cancer-associated VTE, with the critical advantage of dose reduction after 6 months to minimize bleeding while maintaining efficacy 8, 11.